ImpediMed Limited (IPD.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
At close: 03:48PM AEDT
| Previous close | 0.1250 |
| Open | 0.1300 |
| Bid | 0.1050 x 0 |
| Ask | 0.1100 x 0 |
| Day's range | 0.1000 - 0.1320 |
| 52-week range | 0.0490 - 0.1450 |
| Volume | |
| Avg. volume | 1,838,322 |
| Market cap | 191.066M |
| Beta (5Y monthly) | 2.67 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0220 |
| Earnings date | 24 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.15 |
- Simply Wall St.
ImpediMed First Half 2023 Earnings: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022)
ImpediMed ( ASX:IPD ) First Half 2023 Results Key Financial Results Revenue: AU$5.66m (up 8.8% from 1H 2022). Net loss...
- Simply Wall St.
Will ImpediMed (ASX:IPD) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- PR Newswire
New Data Presented at the 2022 San Antonio Breast Cancer Symposium Shows Early Detection using L-Dex and Intervention Improves Lymphedema Progression-Free Survival
ImpediMed Limited (ASX: IPD) is pleased to announce a poster showing that breast cancer patients receiving early detection of lymphedema using ImpediMed's L-Dex® technology and intervention had statistically higher rates of lymphedema progression-free survival through three years compared to using tape measure was presented at the 2022 San Antonio Breast Cancer Symposium on December 6-10, 2022 in San Antonio, Texas.
© 2023 Yahoo. All rights reserved.
